Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease

Abstract

In the version of this article initially published, the Acknowledgments text, now reading "M.S.C. receives funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement no. 948677), the Instituto de Salud Carlos III (PI19/00155), and from the ERC under the EU's 'la Caixa' Foundation (ID 100010434) and from the EU's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant (no. 847648, LCF/BQ/PR21/11840004)," was incomplete and has now been amended in the HTML and PDF versions of the article.

Specific post-translational modifications of the soluble tau protein distinguish between Alzheimer’s disease, 4R-, and 3R-tauopathies

“…Our data on soluble tau also suggests that P-T217 assays may be more specific than P-T231, as was observed in plasma studies. 33 On a more fundamental perspective, our findings are consistent with the view that P-T217, P-T231, P-S262, and P-S396 facilitate tau aggregation, as previously shown in the literature 36,[45][46][47] , whereas P-T212, P-S237, Ub-K267, and P-S404 prevent tau aggregation 48 , highlighting potential targets for the development of tauopathy treatments based on kinases, phosphatases, or ubiquitin signalling enzymes.…”

“…Of note, no phosphorylation site was found specific for AD, although soluble tau P-T217, P-T231 and P-S396 distinguished AD from controls in our data, as reported previously in CSF and plasma [30][31][32][33][34] , post mortem human brain tissue 35,36 , and animal brain tissue 37 . We did not observe pathological hyperphosphorylation of P-T181 in soluble tau, since this site was also phosphorylated in CTLs.…”

The potential clinical value of plasma biomarkers in Alzheimer's disease

“…A 2021 study reported that plasma p‐tau231 levels increased earlier than plasma p‐tau181 levels, indicating that plasma p‐tau231 may be particularly useful for identifying symptomatic individuals who are early in the AD continuum 62 . Two further studies reported that p‐tau231 increases and reaches abnormal levels at lower thresholds of brain amyloidosis than p‐tau217 or p‐tau181 63,64 …”

“…62 Two further studies reported that p-tau231 increases and reaches abnormal levels at lower thresholds of brain amyloidosis than p-tau217 or p-tau181. 63,64 The Elecsys Amyloid Plasma Panel (Roche Diagnostics International Ltd) is a triage tool that comprises a combination of biomarkers. 35 The Elecsys Amyloid Plasma Panel is based on a retrospective study that assessed a panel of Elecsys prototype immunoassays for clinical performance and robustness in three cohorts.…”

Plasma pTau‐217 and N‐terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid‐β positive individuals

“…1,2 However, the development of novel high-sensitivity technologies to quantify ultra-low protein quantities as well as the discovery of novel tau phosphorylation epitopes has resulted in a variety of new promising biomarkers that can be measured in the plasma. [3][4][5] Due to their strong association with imaging-based hallmarks of Alzheimer's disease (AD) pathophysiology and disease progression as well as their non-invasive accessibility, they have great translational potential for clinical use. 6 However, phosphorylated tau (pTau) biomarkers are strongly associated with Aβ and tau brain load, 5,7,8 and therefore it is difficult to determine whether increased pTau levels relate to Aβ or tau aggregates.…”